VIDEO: Long PFS with intermittent panitumumab plus FOLFIRI for colorectal cancer
Click Here to Manage Email Alerts
In this video, Smitha S. Krishnamurthi, MD, discussed the results of the IMPROVE trial, which she said showed significant results in terms of the length of PFS on treatment with an intermittent panitumumab plus FOLFIRI strategy.
The study, presented at ASCO Annual Meeting, evaluated intermittent vs. continuous panitumumab (Vectibix, Amgen) plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer and had a novel primary endpoint of PFS on treatment, Krishnamurthi. a gastrointestinal medical oncologist at Cleveland Clinic, said.
"What was very interesting was that the median progression-free survival on treatment was 20 months in the patients who had the observation," Krishnamurthi said. "It showed that the treatment could keep working over quite a long time."
Collapse
Read more about
Click Here to Manage Email Alerts